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ABSTRACT
Tuberculosis (TB) and the human immunodeficiency virus (HIV) are, individ-
ually, two of the world’s greatest ongoing public health threats. In combination, the two
diseases can be even more devastating. HIV significantly increases an individual’s chances
of reactivation of latent TB infection and progression to active TB disease. HIV’s
associated immunosuppression makes it more difficult to diagnose active TB due to a
higher likelihood of atypical and extrapulmonary presentation and poorer performance of
standard diagnostic tools. TB is the major cause of death in individuals infected with HIV,
and the combination of both illnesses creates unique treatment challenges for providers due
to interactions between antituberculous and antiretroviral medications, overlapping drug
toxicities, and the immune reconstitution inflammatory syndrome. Magnifying these
challenges even further is the fact that much of the burden of TB/HIV coinfection exists
in some of the world’s most resource-limited settings. Concerted efforts are needed to
identify rapid and accurate diagnostic tools for active TB disease and latent TB infection
(LTBI) that are practical and inexpensive and that perform well in individuals with HIV
infection. Also needed are effective and feasible strategies to optimize management of both
conditions in the coinfected patient.
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Mycobacterium tuberculosis (MTB) and the
human immunodeficiency virus (HIV) are pathogens
that, individually, are responsible for two of humankind’s
greatest ongoing health calamities: active tuberculosis
(TB) disease, responsible for 1.7 million deaths world-
wide in 2006,1 and HIV-related diseases, including the
acquired immunodeficiency syndrome (AIDS), respon-
sible for 2.1 million deaths worldwide in 2007.2 In
combination, the two diseases are ever more devastating.
In 2006, 700,000 of the 9.2 million new cases of active
TB and 200,000 of the 1.7 million deaths due to TB
were in individuals also infected with HIV.1
HIV dramatically increases an individual’s chan-
ces of reactivation of latent TB infection (LTBI) and
progression to active TB disease many-fold higher than
any other risk factor,3–5 whereas its associated immuno-
suppression makes it more difficult to diagnose TB due
to a higher likelihood of atypical presentation. TB is
firmly entrenched as the major cause of death in indi-
viduals infected with HIV and creates challenges for
providers when both diseases need to be treated simul-
taneously due to interactions between some antituber-
culous medications and certain antiretroviral drugs,
overlapping drug toxicities, and the common occurrence
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of immune reconstitution inflammatory syndromes.6
With the rise of multidrug resistant (MDR) TB world-
wide7 and extensively drug resistant (XDR) TB in
people infected with HIV,8 these diagnostic and treat-
ment challenges are steadily multiplying. From a
patient’s perspective, having both TB and HIV is partic-
ularly difficult. Both conditions are associated with
stigma and discrimination, and adherence with treat-
ment for both conditions is particularly challenging.
Complicating matters even further is the fact that
much of the burden of TB/HIV coinfection exists in
some of the world’s most resource-limited settings, with
the brunt of that burden being borne by sub-Saharan
Africa where some countries report an HIV prevalence
of greater than 50% among new cases of TB.1 In these
resource-limited settings, patients and providers often
have little to no access to many of the standard diag-
nostic and therapeutic options available to overcome
some of these challenges, and there is often a paucity
of infection control measures, all of which contributes to
the ongoing spread of TB.
ACTIVE TUBERCULOSIS
Diagnostic Challenges
The presence of HIV infection complicates the clinical
presentation of active TB through its effect on the
immune system resulting in changes in the presentation
of active TB disease, which can make diagnosis of active
TB more difficult and delay diagnosis. HIV infection
can lead to paucibacillary disease9 in patients with active
pulmonary TB, which decreases the sensitivity of the
acid-fast sputum smear test,10 the most widely used and
available TB diagnostic method, especially in resource-
limited settings. Patients with HIV, especially advanced
HIV disease, and active pulmonary TB are less likely to
have ‘‘typical’’ chest radiograph findings such as cavitary
lesions and more likely to have chest radiographs
demonstrating lymphadenopathy and/or atypical infil-
trates.11,12 Patients with HIV and active TB are also
more likely to have extrapulmonary TB, especially those
with lower CD4 T cell counts.13
As a consequence of high rates of sputum smear
negativity, atypical chest radiograph findings, and the
increased incidence of extra-pulmonary TB, the diag-
nosis of TB may be missed or delayed in HIV-infected
individuals. Smear-negative TB and delayed diagnosis of
TB in individuals with HIV have both been associated
with increased mortality.14–16 Finally, HIV infection has
been associated with a high prevalence of subclinical TB
in settings of high TB burden,17 further complicating
diagnosis and leading to the need for effective means of
screening for active TB in these populations, especially
prior to initiation of treatment for LTBI.18,19 It is
therefore imperative to develop new rapid and accurate
means for the diagnosis of active TB in HIV-infected
patients with subclinical, smear-negative pulmonary
and/or extrapulmonary TB.
In resource-limited areas, the tuberculin skin test
(TST) is sometimes used to aid in the diagnosis of active
TB. Beyond its lack of specificity for this type of
application and its decreased sensitivity in individuals
with HIV infection, in settings of high TB prevalence
and/or high rates of bacille Calmette-Gue´rin (BCG)
vaccination the TST has been shown to have particularly
limited utility as a diagnostic aid for active TB.9,20
Researchers have looked at improving the speed and
accuracy of active TB diagnosis through the use of
other types of immunologic assays aimed at detecting
TB-specific antibodies21,22 and antigens.23 Thus far,
these strategies, much like the TST, have not yielded
results with acceptable sensitivity or specificity.
Breen et al examined improving the rapidity of
diagnosing smear-negative tuberculosis by performing
rapid immunoassays for MTB purified protein derivative
(PPD)-specific CD4 lymphocytes on the induced sputa
of traditional sputum-smear-negative or sputum-non-
producing TB suspects. Sixteen of their 42 subjects were
HIV infected. Sensitivity and specificity of the immuno-
assay versus final diagnosis of active TB were 89% and
80%, respectively.24 In combination with a single
sputum smear for acid-fast bacilli (AFB) the sensitivity
increased to 93%. Their hopeful results were unaffected
by the HIV status of the individual.
Commercially available MTB nucleic acid
amplification tests (NAATs) have decreased the
time to definitive diagnosis of AFB smear positive
pulmonary TB due to their short turnaround time
and high sensitivity and specificity.25 Resource-limited
settings, however, generally lack the laboratory infra-
structure necessary to reliably perform NAATs for
MTB. In addition, the costs associated with NAATs
are prohibitive in resource-limited settings. For these
tests to become more widely available in resource-
limited settings, the technology required to perform
them must become simpler and their costs must de-
crease substantially.
The challenges associated with implementing
NAAT technology in resource limited settings have
not deterred investigators in those settings from exam-
ining possible uses of such technologies. In a study
conducted in Tanzania on 120 HIV-infected TB sus-
pects (28 of whom were subsequently proven to have
active TB by culture confirmation), Kibiki et al examined
the use of a commercially available whole blood serologic
assay for diagnosis of active TB as well as the use of an
investigator-developed real-time polymerase chain reac-
tion (PCR) for MTB DNA on bronchoalveolar lavage
fluid. The serologic assay fared very poorly in this
HIV-infected group of patients, but the PCR assay
had a sensitivity of 85.7% and a specificity of 90.9%.26




























Though performed on small samples of patients
and a long way from commercial development and
clinical application, especially in settings with limited
resources, studies like the two summarized above high-
light the inventiveness that will be required to tackle the
challenges HIV poses in the diagnosis of TB and lend
hope to the possibility of advances in the near future in
the rapid and accurate diagnosis of TB in patients with
HIV. In this issue of Seminars in Respiratory and Critical
Care Medicine, Drs. Pai and O’Brien (article 9) review
new diagnostics for active TB.
Treatment Challenges
The choices, challenges, complications, and future of the
treatment of HIV-associated active TB have been re-
cently reviewed.6,27,28 In this issue of Seminars,
Dr. Nuermberger (article 7) discusses the use of animal
models to develop new treatments for TB and
Dr. Ginsberg (article 8) reviews emerging drugs for the
treatment of active TB. Treatment of TB and HIV
disease in patients with both conditions presents multi-
ple challenges, including the correct timing of initiation
of antiretroviral (ARV) therapy during TB treatment,
the correct choice of drug combinations to limit inter-
actions, and close patient monitoring to watch for drug
toxicities (which often overlap) and other consequences,
such as immune reconstitution inflammatory syndrome
(IRIS).
It is recommended that antituberculous treatment
be promptly initiated upon diagnosis of TB in an effort
to decrease mortality and infectiousness.29,30 Addition-
ally, emphasis has been placed on starting ARV therapy,
when indicated, during TB treatment due to the high
morbidity and mortality in patients with HIV coinfec-
tion even when receiving appropriate antituberculous
treatment.31 The World Health Organization recom-
mends that the timing of initiation of ARV therapy in
these patients be based on the degree of immunosup-
pression as defined by CD4 cell count.32 Although not
an unreasonable approach, further research is necessary
to better define the optimal time for initiation of ARV
therapy during TB treatment.
Several factors may complicate concurrent ARV
therapy, including additive toxicities of medications,
drug interactions, risk of immune reconstitution events,
and difficulty in medication adherence.33 Despite these
challenges, use of ARV therapy for those who qualify
during TB treatment is important because it improves
outcomes and decreases mortality.34 The choices of
ARVs that can be used safely during TB treatment are
severely limited by the necessary use of rifampin
(or other rifamycins) in most regimens for the treatment
of rifampin-susceptible TB due to rifampin’s effect
on the metabolism of antiretroviral drugs resulting
in severely reduced levels of protease inhibitors (PIs),
significantly reduced levels of the nonnucleoside reverse
transcriptase inhibitor (NNRTI) nevirapine, and mild to
moderate reductions in the level of efavirenz, another
NNRTI.
The Centers for Disease Control and Preven-
tion (CDC) has recently released guidelines on the
management of drug interaction in the treatment of
HIV-associated TB.35 In resource-limited settings, ne-
virapine-based regimens are used in most national ARV
treatment programs but coadministration with rifampin
is not recommended. Efavirenz-based ARV regimens
are recommended in this scenario. However, it is unclear
if standard dosing of efavirenz is adequate to compensate
for any increases in efavirenz metabolism due to the
concomitant use of rifampin.36 Matters become more
complicated in the treatment of HIV-associated TB
in pregnant women, a setting in which efavirenz is
not recommended, and children, whose first-line ARV
regimens often include PIs.
A few projects have assessed coadministration of
these antituberculous and ARV agents with excellent
preliminary results.34,37 A recent retrospective study in
Thailand comparing HIV/TB coinfected individuals
receiving rifampin-based TB therapy who started ARV
therapy with either efavirenz or nevirapine at standard
doses encouragingly showed no difference in virologic
and CD4 outcomes between the two ARV treatment
groups, though this study may have been underpow-
ered.38 More pharmacokinetic and larger prospective
and randomized clinical studies using various interven-
tions and monitoring tools are urgently needed in
patients receiving concomitant antituberculous and
antiretroviral drugs to determine the exact risks and
benefits of the various guidelines currently in use. The
feasibility and effectiveness of rifabutin, which is less
prone to drug interaction, in resource limited settings
should also be urgently evaluated.
Paradoxical worsening of TB in HIV-negative
patients after initiation of effective treatment for active
TB is a long recognized clinical entity; in HIV-associ-
ated TB the rates of paradoxical worsening in patients on
TB treatment who then start ARV therapy are much
higher,39 likely due to ARV therapy’s beneficial effect on
the immune system, and have been categorized as one of
the many types of immune reconstitution inflammatory
syndromes (IRIS) that patients with HIV are prone to
developing after initiation of ARVs.40 The incidence of
TB-IRIS in HIV/TB coinfected individuals receiving
therapy for both diseases varies from study to study but is
likely in the range of 20 to 30% of patients.41 TB-IRIS
poses significant challenges to providers because there is
no single diagnostic test that can distinguish TB-IRIS
from treatment failure (an especially difficult problem in
resource-limited settings where culture and drug sus-
ceptibility testing is often unavailable to help distinguish
the two), no agreed upon case definition of IRIS, and no




























prospective or randomized trial data on how to best treat
and manage TB-IRIS. More research in these areas is
urgently needed.
Infection control measures for inpatient and out-
patient settings need to be put into place whenever and
wherever HIV-associated tuberculosis is being managed
but perhaps most importantly in resource-limited set-
tings,42 where the association between HIV and MDR-
and XDR-TB secondary to hospital-based transmission
and spread has highlighted the need for better preventive
practices.8 Improved infection control measures and
increased program capacity in such settings are necessary
to avoid further overwhelming the public health sys-
tem.43 To be successful, however, not only will increased
resources be necessary, but, in addition, TB and HIV




Despite its shortcomings, which include lower sensitivity
in HIV-infected patients45,46 and cross-reactivity with
components of the BCG vaccine, the TST is the accepted
standard for diagnosis of LTBI. HIV-infected individu-
als with LTBI, as defined by lack of symptoms or signs
consistent with active TB and with a positive TST, have a
higher risk for reactivation than HIV-uninfected indi-
viduals with LTBI.3–5,47 In many resource-limited set-
tings, however, tuberculin skin testing is rarely available
for a variety of reasons, including lack of access to clean
needles and syringes for planting PPD and unavailability
of properly refrigerated storage facilities for tuberculin.
In recent years, advances in LTBI diagnostics
have been spurred by the elucidation of the Mycobacte-
rium tuberculosis genome and the characterization of TB-
specific antigens.48,49 These TB-specific antigens have
led to the development of diagnostic tests for LTBI
based on interferon-gamma production by T cells stimu-
lated by these antigens,50 and have been dubbed inter-
feron-gamma release assays (IGRAs). Three IGRAs are
now commercially available: the QuantiFERON-TB
Gold and the QuantiFERON-TB Gold In-Tube (Cel-
lestis Inc., Valencia, CA), and the T-SPOT.TB (Oxford
Immunotec Limited, Abingdon, Oxfordshire, UK) .
The QuantiFERON is approved for use in the United
States, with approval for the T-SPOT.TB expected to be
imminent at the time of this writing. In this issue of
Seminars, Drs. Pai and O’Brien (article 9) review these
new diagnostics for LTBI. In brief, IGRAs have been
shown, in immunocompetent adult subjects, to have
excellent specificity for TB infection and good to ex-
cellent sensitivity for LTBI. The CDC has issued guide-
lines on the use of the QuantiFERON but cautions that
it has not been extensively studied in children and
immunocompromised individuals and that it may have
a different sensitivity in these populations.51
Studies examining the performance of these new
T cell–based IGRAs in immunocompromised and HIV-
infected individuals have had mixed results. Some stud-
ies have shown the enzyme-linked immunosorbent assay
(ELISA)-based tests to have an increased incidence
of indeterminate results52–54 in these populations.
Other studies have shown the evaluability and perform-
ance of the enzyme-linked immunospot (ELISPOT)
assay–based tests to not be affected or to be affected to
a lesser degree by the absolute CD4 T cell count,55–57
but a more recent study has challenged these findings.58
Larger studies examining the sensitivity, performance,
and predictive value of IGRAs in patients with HIV are
needed to allow providers to make the most informed
decisions about who should receive treatment for LTBI.
Treatment Challenges
Adherence to and completion of treatment for LTBI are
key to maximizing its effectiveness. Low perceived bene-
fits of treatment increases the risk of noncompletion,59 but
shorter regimens have been shown to improve completion
rates.60 In this issue of Seminars, Dr. Sterling (article 6)
reviews new strategies for the treatment of LTBI.
Randomized trials in resource-limited settings
have shown that the use of isoniazid (INH) for treat-
ment of LTBI in HIV-infected patients can reduce the
incidence of TB61,62 and is cost-effective,63 but that
benefit may wane over time,64 probably because of the
high likelihood of reinfection in high TB burden set-
tings.65 Another challenge to the successful treatment of
LTBI in people infected with HIV in these settings
includes a hesitancy on the part of many National TB
Control Programs in implementing LTBI treatment
programs using INH for fear that patients started on
this regimen may, in fact, have undiagnosed active TB,
especially subclinical, smear-negative, or extrapulmonary
TB, and thus would inadvertently receive monotherapy
for active TB disease resulting in emergence of drug
resistant TB. Systematic and standardized screening for
active TB in high TB burden and resource-limited
settings leads to increased case detection17,66 but it is
unclear how sensitive these strategies are and whether
they can confidently be used to rule out all active TB
disease prior to treatment for LTBI. Developing diag-
nostic tools and screening algorithms that can accurately
diagnose LTBI in individuals with HIV while excluding
active TB are areas needing further investigation.
CONCLUSION
HIV-related TB is a major global health threat.
All currently available diagnostic methodologies in use
are suboptimal in individuals with concomitant HIV




























infection. Concerted efforts are needed for the develop-
ment of new rapid and accurate diagnostic tools for active
TB disease and LTBI that perform well in patients with
HIV disease.
In resource-limited settings where the greatest
burden of HIV-associated TB exists, many of the tests
described here, with the exceptions of the TST and
sputum smear, are prohibitively expensive and/or require
sophisticated laboratory infrastructure. Thus new diag-
nostic tools for TB and LTBI are needed that are
practical, inexpensive, and feasible to implement in
resource-limited settings.
Many unanswered questions and challenges also
remain in the management and treatment of HIV-
related TB, including the optimal timing of initiation
of ARV therapy, the safest and least interaction-prone
combinations of antituberculous and ARV drugs, and
accurate and effective methods for diagnosis and man-
agement of TB-IRIS. Further clinical research, partic-
ularly prospective and randomized trials, is needed to
answer the open questions in this area.
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